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Traumatic brain injury (TBI) results in systemic inflammatory responses that affect the lung. This 
is especially critical in the setting of lung transplantation where more than half of donor allografts 
are obtained postmortem from individuals with TBI. The mechanism by which TBI causes 
pulmonary dysfunction remains unclear but may involve the interaction of high mobility group 
box 1 (HMGB1) protein with the receptor for advanced glycation end products (RAGE). To 
investigate the role of HMGB1 and RAGE in TBI-induced lung dysfunction, RAGE sufficient 
(wildtype) or deficient (RAGE−/−) C57BL/6 mice were subjected to TBI through controlled 
cortical impact and studied for cardio-pulmonary injury. Compared to control animals, TBI 
induced systemic hypoxia, acute lung injury, pulmonary neutrophilia and decreased compliance, 
all of which were attenuated in RAGE −/− mice. Neutralizing systemic HMGB1, induced by TBI, 
reversed hypoxia and improved lung compliance. Compared to wildtype donors, lungs from 
RAGE−/− TBI donors did not develop acute lung injury after transplantation. In a study of clinical 
transplantation, elevated systemic HMGB1 in donors correlated with impaired systemic 
oxygenation of the donor lung pre-transplantation and predicted impaired oxygenation post-
transplantation. These data suggest that the HMGB1-RAGE axis plays a role in the mechanism by 
which TBI induces lung dysfunction and that targeting this pathway prior to transplant may 
improve recipient outcomes following lung transplantation.
Introduction
In addition to the lesions caused at the moment of injury, brain trauma can result in 
secondary damage, which includes a variety of events that take place in the subsequent hours 
and days after injury. Included in the possible secondary injury types are indirect effects on 
the pulmonary system including acute respiratory distress syndrome (ARDS) and acute lung 
injury (ALI). This is particularly relevant in the context of lung transplantation where the 
majority of donor lungs are procured from brain-dead donors, of which between 40–70% 
have sustained traumatic brain injury (TBI) (1). Of those evaluated only approximately 15% 
are deemed suitable for transplant (2). The mechanisms by which TBI leads to pulmonary 
dysfunction are poorly understood. Historically, a combination of catecholamine surge-
induced pulmonary vascular permeability, as well as production of inflammatory mediators 
are thought to compromise lung function (3). There is evidence that systemic inflammatory 
factors cause pulmonary injury and dysfunction (4).
Recent approaches to identifying the pathophysiological mechanisms of acute lung injury 
have focused on non-traditional pro-inflammatory mediators and their receptors. In 
particular is the class of danger-associated molecular patterns (DAMPs; alarmins), which are 
often associated with sterile inflammatory responses to events such as ischemia or systemic 
disease. A DAMP of particular interest is high mobility group box-1 (HMGB1). Though 
HMGB1 is typically associated with chromatin, it can be quickly released into the cytoplasm 
following stress, injury, or disease. Depending on the status of the affected cells, cytoplasmic 
HMGB1 can be passively released into the extracellular space. Alternatively, HMGB1 can 
be actively released by cells of the immune and nervous systems following injury, 
inflammation, or disease (5–7). Progress to date suggests that HMGB1 receptors include 
toll-like receptor 4 (TLR4) and receptor for advanced glycation end products (RAGE) (8). 
Both TLR4 and RAGE are expressed by many cell types including those in the lung (12) and 
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participate in the onset of innate immune inflammatory processes through activation of NF-
κB (13, 14). HMGB1 binding to RAGE has also been implicated in a number of 
inflammation-associated diseases including cancer, diabetes, epilepsy, and Alzheimer’s 
disease (9–11). It is well established that RAGE is constitutively expressed at high levels in 
the lung (12), and RAGE ligation leads to sustained activation of NF-κB and increased 
RAGE expression, which ensure maintenance and amplification of an inflammatory signal 
(13, 14).
In this study, we examined the involvement of HMGB1 and RAGE in TBI-induced acute 
lung injury in mice whose lungs were utilized as donors for transplantation. We also used 
clinical samples to explore the connection between elevated donor HMGB1 and pulmonary 
dysfunction before and after lung transplantation. As HMGB1 is known for its contribution 
to proinflammatory processes associated with injury and organ damage associated with 
severe sepsis, TBI disruption of the blood-brain barrier and the release of DAMPs could 
trigger an inflammatory cascade in tissues rich in RAGE receptors, most prominently the 
lungs (15–18). In an effort to characterize the cause of pulmonary dysfunction after TBI and 
the role of the HMGB1-RAGE axis, we studied lungs obtained from mice either deficient or 
sufficient in RAGE prior to being utilized as donors for transplantation. Local and systemic 
inflammatory responses as well as pulmonary function in both donors and recipients were 
analyzed. Translational studies examined the correlation of systemic HMGB1 concentrations 
and indices of acute lung injury in human lung transplant donors before donor harvest and in 
recipients after lung transplantation. Our objective was to determine whether TBI-induced 
inflammatory changes result in pulmonary dysfunction that is dependent on the HMGB1-
RAGE pathway.
Results
TBI Induces Acute Lung Injury and Increased Systemic HMGB1
TBI caused substantial changes in lung architecture of C57BL/6 mice. These animals had 
evidence of alveolar hemorrhage at 4 and 8 hours post injury compared with sham-injured 
mice. By the 12 and 24 hour time points, this alveolar hemorrhage largely had resolved (Fig. 
1A–E). However, these lungs did continue to have evidence of acute lung injury as 
evidenced by proteinaceous debris and neutrophilic infiltration. As scored by a standardized 
assessment (19), lungs from animals subjected to TBI had higher acute lung injury scores 
than control lungs at the same time intervals (Fig. 1F). The mean score for sham-injury 
control lungs was 0.09 ±0.03 while scores at the 4 hour time point after TBI yielded a 
significantly higher score of 0.62 ±0.11 (p < 0.01). Scores remained significantly elevated at 
8, 12, and 24 hours after TBI with scores of 0.47 ±0.11, 0.49 ±0.16, and 0.56 ±0.15, 
respectively (all p < 0.01). Additionally, the amount of alveolar hemorrhage at the 4 and 8 
hour time points corresponded with acute lung injury scores.
Consistent with neutrophilia in the lung were data showing that myeloperoxidase (MPO), a 
neutrophil-derived enzyme, was greater in mice subjected to TBI compared to controls (327 
±14.7 vs. 161 ±12.7 ng/mL, respectively, p<0.01, Fig. S1). Activated caspase-3 staining, a 
marker for apoptosis that can occur during tissue injury of many types including the lung, 
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was not increased in either C57BL/6 or RAGE−/− TBI mice compared to sham TBI mice 
(Fig. S2).
Albumin was quantitated in bronchalveolar lavage fluid (BAL) after TBI to determine if 
increased vascular permeability was associated with the acute lung injury scores. In healthy 
mice subjected to sham injury, the BAL albumin concentration was 52.5 ± 11.2 μg/mL. 
Albumin concentrations were significantly higher at 4 hours post TBI (303 ± 21.0 μg/mL) 
then declined progressively at 8 (301 ± 34.1 μg/mL), 12 (212 ± 17.9 μg/mL), and 24(103 
± 22.1 μg/mL) hours (Fig. 1G). However, compared to controls, all BAL albumin levels 
were increased significantly at each time point indicating TBI-induced vascular permeability 
(p < 0.01).
To determine if HMGB1 increased following TBI, serum HMGB1 levels from sham-injured 
wildtype mice as well as TBI wildtype mice were assayed at 24 hours (Fig. 1H). In sham-
injury control animals, the mean serum HMGB1 concentration was 1.8 ± 0.4 ng/mL. 
However, TBI-induced significantly higher HMGB1 levels compared to controls (4.1 ±0.7 
ng/mL, p < 0.01). Even higher levels were seen with RAGE −/− mice (7.9 ± 2.6 ng/ml, p < 
0.01).
RAGE and HMGB1 Profiling
In an effort to confirm that RAGE, a key receptor for HMGB1, is organ specific, Western 
blots were performed using homogenates of lung, spleen, liver, and spinal cord from three 
wildtype mice. High levels of RAGE were present in the lung samples but not the other 
tissue types (Fig. S3). To localize possible serum sources of HMGB1, we profiled HMGB1 
in both the lungs and cortical tissue ipsilateral to the TBI in sham and TBI mice. Although 
nuclear HMGB1 was observed in the lungs of both sham and TBI mice, there was no 
evidence of the loss of nuclear HMGB1 immunopositive signal (Fig. S4). In contrast, 
cortical tissue associated with the lesion site exhibited a pronounced decrease in the number 
of cells which were immunoreactive for HMGB1 when compared with adjacent, uninjured 
cortical areas 24 hours after TBI. The observed loss of cellular HMGB1in injured tissue did 
not appear to be associated with TBI-induced cell loss as numerous cells within the lesion 
site retained nuclear staining with DAPI (Fig. S5).
TBI Induces Pulmonary Dysfunction
Groups of wildtype C57BL/6 mice were subjected to severe TBI injury followed by 
assessment of systemic oxygenation as determined by PaO2/FiO2 ratios 4 – 24h post TBI 
(Fig 2A). This ratio divides the aterial oxygentation concerntation by the fraction of inspired 
oxygen where increasing values reflect improved ability of the lung to absorb oxygen from 
air. The sham-injury control group, PaO2/FiO2 ratios were normal at 578 ± 5.23. However, 4 
hours after TBI the PaO2/FiO2ratio decreased to 351 ±2.55 and continued to decline at 24 
hours (111.5 ±13.09). Pulmonary function testing at the same intervals demonstrated a 
similar time-dependent decline in compliance (measure of the lungs ability to expand) (Fig. 
2B). For the sham-injury control group, compliance was 0.0315 ±0.0004 mL/cmH2O. By 
eight hours after TBI, compliance decreased to 0.0286 ±0.0008 (p = 0.01) mL/cmH2O and 
continued to decline for up to 24 hours. Compliance at 24 hours was 0.0205 ±0.0006 
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mL/cmH2O, which was significantly lower than the control group (p <0.01). Airway 
resistant values were also recorded but did not differ between the groups (Fig. S6).
Pulmonary Dysfunction due to TBI is diminished in the lungs of RAGE−/− mice
In a separate group of experiments, we determined the role of RAGE in TBI-induced lung 
dysfunction. Wildtype C57BL/6 and RAGE −/− mice were subjected to moderate or severe 
TBI and PaO2/FiO2ratios were assessed at 24 hours. The moderate and severely injured 
wildtype C57BL/6 mice exhibited low PaO2/FiO2values at 358 ±14 and 221 ±14, 
respectively. These values were significantly lower than the sham-injury control mice (554 
± 9.25) (p<0.01) (Fig. 2C). In contrast, RAGE −/− mice subjected to moderate TBI exhibited 
PaO2/FiO2ratios that registered at 541± 8.06 and did not differ from sham-injury PaO2/
FiO2ratio values (p = 0.32). Similarly, RAGE −/− mice with severe TBI did not appear to be 
compromised by the injury with a PaO2/FiO2ratio of 447 ± 3.4, which was significantly 
higher than for the wildtype C57BL/6 mice subjected to the same severe TBI (p<0.01). 
Static compliance was also assessed in wildtype C57BL/6 and RAGE −/− mice subjected to 
moderate and severe TBI. Static compliance in sham control animals was 0.034 ±0.0003 
mL/cmH2O, whereas compliance declined 24 hours after moderate or severe TBI to 0.0302 
±0.0006 mL/cmH2O or 0.0226 ±0.0009 mL/cmH2O, respectively (p<0.01). Compliance 
values were improved significantly in RAGE −/− mice subjected to severe injury with a 
mean value of 0.0317 ±0.0006 mL/cmH2O compared to the wildtype group subjected to the 
same injury (p<0.01) (Fig. 2D). Such results indicate that RAGE plays a major role in the 
pulmonary dysfunction seen in wildtype mice.
TBI causes Lung Dysfunction in TLR4 −/− Mice
In an effort to determine the degree to which TLR4, a key HMGB1 receptor, may contribute 
to lung dysfunction, we subjected TLR4 −/− mice to severe TBI and performed functional 
analyses after 24 hours. All studies were repeated with groups of mice separate from those 
reported in figures 1 and 2. The values from TLR4 −/− mice were compared with a new set 
of RAGE −/− mice subject to the same brain injury. The mean PaO2/FiO2ratio in the TLR4 
−/− mice was 355 ±28 which was significantly lower than values present in control wildtype 
mice and RAGE −/− TBI mice (p < 0.01, Fig. 3A). Additionally, the static compliance value 
in the TLR4 −/− mice was 0.0220 ±0.0040 mL/cmH2O, again significantly lower than the 
control and RAGE −/− mice groups (p < 0.01, Fig. 3B).
Effect of Neutralizing HMGB1 on Lung Dysfunction
To determine if HMGB1 is the primary ligand activating RAGE or TLR4 following TBI, 
wildtype C57BL/6 mice were treated with a HMGB1 neutralizing antibody (HMGB1 Ab) or 
control antibody prior to TBI. HMBG1 Ab treatment resulted in a PaO2/FiO2ratio of 408 
±15.6 at 24 hours after TBI (Fig. 3A) with a mean compliance of 0.0272 ±0.0015 (Fig. 3B). 
These values with the neutralizing antibody were significantly improved compared to values 
observed with the control antibody or in wildtype mice post TBI (p < 0.01). However, these 
values were not different from those observed in TLR4 −/− mice (Fig. 3A,B).
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Preservation of Lung Function using a Toll/IL-1 receptor domain-derived decoy peptide
Toll-like receptors utilize common Toll-/Interleukin-1R Resistance domains (TIR), which 
are pivotal to both interactions of signaling proteins and signal transduction (20). As TLR 
TIR dimers serve as recruitment centers for TLR adapter proteins, it is possible to inhibit 
cellular signaling downstream of TLR4 using cell permeable decoy peptides as competitive 
inhibitors of protein-protein interactions (21). TIRAP and MyD88, known adaptor proteins 
for Toll-like receptor-4, also bind to phosphorylated RAGE (22, 23). Using the cell-
permeating decoy peptide, TAT-4BB, to inhibit surface exposed segments of these adapter 
proteins, we targeted the ability of HMGB1 to produce signaling in vivo via either TLR4 or 
RAGE (24). Wildtype C57BL/6 mice were administered a TAT-4BB decoy peptide before 
exposure to severe TBI. The mean PaO2/FiO2ratio in these animals was 487.8 ±31.14 at 24 
hours post injury, which was significantly higher than values derived from the TLR4 −/− 
TBI mice (p=0.01) but did not differ from RAGE −/− mice (p=0.22, Fig. 3A). Additionally, 
the static compliance value in the decoy peptide 4BB-treated mice was 0.0286 ±0.0050 
mL/cmH2O, which did not differ from TLR4 −/− (p =0.33) or RAGE −/− mice (p = 0.55, 
Fig. 3B).
TBI induces pulmonary dysfunction in the setting of preserved cardiac output
In an effort to ensure that TBI-induced pulmonary dysfunction was non-cardiogenic in 
nature, we utilized gated PET scans to calculate cardiac outputs from four sham-injury 
control mice and four mice 24 hours after severe brain injury (Fig. S7A). The data showed 
that there was no significant difference in heart rates between control animals (440.4 ±32.3 
bpm) and TBI mice (441.7 ±18.8 bpm) (Fig. S7B). TBI mice did exhibit elevations in 
average stroke volumes (0.0436 ± 0.0026 mL) when compared with sham-injury control 
volumes (0.034± 0.0017 mL) (Fig. S7C). Despite the elevated stroke volumes in the sham-
injury group, there was not a significant difference in cardiac output between the groups.
Murine lung transplant recipients from TBI donors exhibit elevated lung injury scores 
compared to recipients from RAGE −/− TBI donors
Acute lung injury scores (Fig. 4) were significantly lower in transplanted lungs from 
wildtype control donors (Fig. 4A) at 0.12 ± 0.02 when compared to TBI donors with a mean 
score of 0.44 ± 0.08 (p < 0.01, Fig. 4B). The means scores in transplanted lungs from TBI 
RAGE −/− donors was 0.17 ± 0.03 (minimal injury) and these lungs were otherwise 
histologically normal (Fig. 4C, D). This score was significantly lower than that for the 
wildtype C57BL/6 donor group (p < 0.01). Such results demonstrate that eliminating RAGE 
appears to preserve pulmonary injury post-transplantation.
Elevated IL-10 in TBI RAGE−/− Mice and Recipients of Lungs from TBI RAGE−/− Mice
IL-4, IL-6, IL-17a, TNF-α, and IFNγ BAL levels did not differ among donor sham-injured 
controls, TBI wildtype, and TBI RAGE −/− donor mice (Fig 5A–E). However, RAGE −/− 
donor mice had significantly higher levels of the anti-inflammatory molecule, IL-10, in BAL 
fluid (MFI 530.0 ± 23) when compared with sham controls (MFI 331.5 ±16) or TBI 
wildtype mice (MFI 408.5 ±13) (p<0.01) (Fig. 5F). Cytokine profiling was also determined 
in BAL fluid of transplanted lungs of mice whose donors were either TBI wildtype or RAGE 
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−/− mice. These transplants were performed 24 hours after sham or TBI. Cytokine profiling 
in the BAL fluid of recipients 8 hours post-transplant revealed no differences in IL-4, IL-6, 
IFNγ, TNF-α, and between wildtype and RAGE−/− donor lungs (Fig. 5A,B,D,E). IL-17a 
was significantly lower in the BAL fluid of recipients when the left lung was derivedfrom a 
RAGE −/− TBI mice: 245 ± 63.4 versus 602 ± 33.2 for TBI wildtype C57BL/6 control mice 
(p<0.01, Fig. 5C). Similar to observations in mice subjected to TBI alone, IL-10 was 
significantly elevated in BAL from transplanted lungs from RAGE −/− TBI donors 
compared to transplanted lungs from wildtype C57BL/6 TBI donors (1846 ± 19.6 versus 
1241 ± 21.3, p<0.01, Fig. 5F).
HMGB1 Stimulates NF-κB Activation in Airway Epithelial Cells
In an effort to determine the downstream signaling pathways activated by HMGB1 binding 
to RAGE in the lungs, we stimulated rat alveolar type 2 epithelial cells with increasing 
concentrations of the non-oxidized (all-thiol) form of HMGB1 that binds only to RAGE. 
Translocation of NF-κB p65 and p50 from the cytoplasm to the nucleus, an indication of 
NF-κB activation, was enhanced 24 hours after stimulating AT2 cells with at least 10μg/mL 
of HMGB1 (Fig. 6).
Elevated donor HMGB1 correlates with poor blood oxygenation before and after human 
lung transplant
Blood was collected from human brain dead donors prior to procuring lungs to be utilized 
for bilateral lung transplants. Donor, recipient, and surgery specific characteristics are 
presented in Table 1. All blood samples were obtained from brain dead organ donors: 11 of 
the 18 died from TBI, the rest died of other causes including 4 from anoxia and 3 from 
stroke. The correlation between donor serum HMGB1 concentrations and the highest PaO2/
FiO2ratio prior to procurement was determined. HMGB1 concentrations correlated inversely 
with donor PaO2/FiO2 ratios, where high HMGB1 levels were associated with lower PAO2/
FIO2 ratios (p<0.01, Fig. 7A). This correlation was maintained when the data included only 
the subset of 11 donors that died from TBI (p=0.05, Fig. 7B). To examine the association 
between donor HMGB1 and recipient lung function, donor HMGB1 serum concentrations 
were correlated with recipient PaO2/FiO2ratios 48 hours after lung transplant. Linear 
regression revealed that donor HMGB1 concentrations also correlated inversely with 
recipient PaO2/FiO2ratios 48 hours after transplant, both in the 18 brain dead donors 
(p<0.01) as well as in the 11 TBI donors (p<0.01, Fig. 7C, D).
Discussion
Our results demonstrate that the HMGB1-RAGE ligand-receptor pathway serves as a central 
signal transduction mechanism for pulmonary dysfunction after TBI. TBI induced 
alterations in physiology and histology included reduced systemic arterial oxygen, decreased 
lung compliance, and pathology consistent with acute lung injury. These findings were 
RAGE-dependent as systemic oxygenation, lung compliance, and histology were restored 
almost completely to baseline in RAGE−/− mice subjected to TBI. Considering that a 
majority of lungs utilized for transplant are obtained from patients who have suffered a TBI, 
factors such as donor HMGB1 serum concentration may be predictive of lung function 
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before and after transplantation. Our current clinical data suggest that brain injury-induced 
HMGB1 release may have a role in donor and short-term recipient pulmonary function as 
well.
It is well established that pro-inflammatory molecules including HMGB1 are ligands for 
RAGE (25). Though initial reports suggested that extracellular HMGB1 released by necrotic 
and inflammatory cells functions as a late-acting cytokine mediating endotoxin-related 
lethality in mice (26) and cytokine synthesis in monocytes (27), there has been greater 
recognition that the effect of HMGB1 activation of RAGE has acute effects on leukocyte 
chemotaxis and vascular barrier disruption (28–30). Moreover, these effects may be 
important for sustaining inflammatory disease conditions alone (22) or in combination with 
toll-like receptors (31–34). Furthermore, our results with HMGB1 cortical staining 
demonstrating HMGB1 translocation from the nucleus after TBI agrees with reports 
demonstrating HMGB1 translocation and release after brain insult (35).
A recent report demonstrated that neutralization of HMGB1 may be a new treatment for 
brain injured animals due to reductions in brain edema and inflammation (36). Given our 
results, these beneficial effects can now be extended to the lungs. Given the ability of 
HMGB1 to bind to both RAGE and TLR4, our experimental outcomes implicate a 
pronounced role for RAGE as the lung dysfunction was more pronounced in the setting of 
TLR4 deficiency as compared to RAGE deficiency. One interpretation suggests that 
HMGB1-RAGE is instrumental for leukocyte infiltration while HMGB1-TLR4 may be 
responsible for cytokine production (37–40). Alternatively, it is known that HMGB1 can 
exist in either of two isoforms, all-thiol and disulfide, which have varying specificity for 
RAGE and TLR4. The all-thiol state of the isoform is first released into the extracellular 
space where it binds to RAGE and initiates chemoattraction of leukocytes (41). In contrast, 
the disulfide isoform exhibits a high affinity for TLR4 and induces the release of 
proinflammatory cytokines and mediators (42). Compared to the half-life of all-thiol (~17 
minutes), the disulfide isoform’s half life is significantly longer (up to 10 hours) (43). 
Considering the kinetic differences between the isoforms and the rapid induction of lung 
injury post TBI, it is apparent that the all-thiol form of HMGB1 binding to RAGE may be 
the primary pathway of lung injury in the current study. This finding is also supported by our 
data showing that the all-thiol form of HMGB1 induced NF-κB activation in airway 
epithelial cells. However, the exact contribution of both HMGB1 isoforms in TBI-induced 
lung injury is yet to be established.
The effects of the TAT-4BB decoy peptide and its ability to modulate TBI-induced 
inflammation is likely dependent on the adapter proteins common to both TLR4 and RAGE 
(22), though there is a suggestion that the HMGB1-TLR4-RAGE interaction is central to the 
downstream signaling (44). However, given the apparent commonality of downstream 
signaling for both TLR4 and RAGE, we hypothesize that decoy peptides would inhibit TBI-
associated changes in pulmonary tissue and physiology regardless of the signaling receptor.
Ligand-dependent activation of RAGE may modulate chemotactic actions of leukocytes. Our 
results reinforce prior reports that HMGB1 may stimulate RAGE activation of NF-κB (45), 
so it is conceivable that pulmonary dysfunction following TBI include the production of pro-
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inflammatory cytokines such as IL-6, TGF-β and IL-17a (45–48). However, the only 
cytokine that appeared to be altered in the BAL following injury was the anti-inflammatory 
cytokine, IL-10. Together with previous observations in a model of hemorrhagic shock (49) 
and a recent report suggesting that signaling via RAGE is linked to downregulation of IL-10, 
it appears that modulation of this important anti-inflammatory cytokine is regulated by 
RAGE activation. More importantly, it is possible that increased IL-10 concentrations could 
dampen the inflammatory process and mitigate injury to the pulmonary system. An example 
of such an effect may be evidenced by the beneficial effects of soluble RAGE administration 
in IL-10 null mice subjected to chronic colonic inflammation (50). In addition, IL-10 gene 
therapy has been utilized to repair donor human lungs prior to transplantation (51).
Other work using an ischemia reperfusion injury model demonstrated that the HMGB1-
RAGE pathway contributes to IL-17a production from invariant natural killer cells, which 
are crucial for the initiation of ischemia reperfusion injury (17). Our results corroborated this 
concept of HMGB1-RAGE mediated effects on cytokine production in ischemia reperfusion 
injury We observed decreased IL-17a protein expression in the BAL of recipients of RAGE
−/− TBI donor lungs as compared to recipients of wildtype TBI donor lungs. Additionally, 
the connection between RAGE and lung dysfunction has been studied outside of the setting 
of TBI. Circulating soluble RAGE was reported to be a marker of primary graft dysfunction, 
which is a form of ischemia reperfusion injury that occurs after lung transplantation (52).
Non-cytokine pathways have also been linked to TBI-induced lung injury. A recent report 
implicated high levels of glutamate after brain injury triggering acute lung injury mediated 
through interaction of the adenosine A2A receptor and the metabotropic glutamate receptor 
5 (mGluR5) on bone marrow-derived cells (53). This pathway may run in parallel to the 
HMGB1-RAGE axis with overlap of downstream signaling.
In summary, the current study demonstrates a mechanism of TBI-induced acute lung injury 
that includes a key role for the HMGB1-RAGE pathway. These data may be important for 
preventing pulmonary complications in patients after TBI. These findings could also have 
implications in the field of lung transplantation. Most lungs for transplantation are procured 
from patients after TBI. Remarkably, only 15–20% of such lungs are suitable for transplant 
due to abnormal physiology that includes impaired oxygenation, a critical parameter of lung 
function. Given that TBI has profound detrimental effects on pulmonary physiology, the 
current study suggests that targeting the RAGE-HMGB1 axis could serve as a new 
therapeutic approach to increase the quality of lungs suitable for transplantation.
Materials and Methods
Study Design
This study was designed to identify the role of the HMGB1-RAGE inflammatory pathway in 
TBI-induced pulmonary dysfunction. To do this, we utilized murine models of traumatic 
brain injury and lung transplantation in wildtype and transgenic mice as further described 
below to better understand the pathways at work. We also administered an HMGB1 
neutralizing antibody as well as a downstream signaling decoy peptide to further delineate 
the downstream signaling. Additionally, we utilized our institution’s prospectively collected 
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lung transplant biobank to correlate donor levels of HMGB1 with donor and recipient lung 
function.
Human Studies
All human studies were approved by the Indiana University Institutional Review Board. 
Additionally, all lung transplant recipients consented and all donor families consented for 
organ donation and research. Using a prospectively collected samples from lung transplant 
recipients and donors, we identified donor cause of death and donor serum levels of HMGB1 
using an ELISA kit (IBL International, Hamburg, Germany) and correlated with donor 
pulmonary function values and short-term recipient pulmonary values and outcomes.
Animals
All mice were housed in the Laboratory Animal Resource Center at Indiana University 
School of Medicine in accordance with institutional guidelines. All mice were 8–12 weeks 
of age and 24–32g and used as both donors and recipients. Mice were randomly assigned to 
groups. All studies were approved by the Laboratory Animal Resource Center at the Indiana 
University School of Medicine. Specific pathogen-free male inbred mice C57BL/6 were 
purchased from Harlan Sprague-Dawley (Indianapolis, IN). TLR4 −/− mice were purchased 
from Jackson Laboratory (Bar Harbor, ME) and RAGE −/− mice were obtained from onsite 
colonies (54).
Traumatic Brain Injury (TBI)
Mice were subjected either to a TBI using a controlled cortical impact model using an 
electromagnetic impactor (Impactor One™, MyNeuroLab) or sham-injury (55). The mice 
were anesthetized with isoflurane and ketamine and placed in a stereotaxic frame (Kopf 
Instruments, Tujunga, CA). The skull was exposed in the left fronto-pareital cortex using an 
electric drill. Prior to the injury, the impacting piston was angled so that the impacting tip (3 
mm in diameter) was perpendicular to the exposed cortical surface. This was accomplished 
by rotating the entire stereotaxic frame on the transverse plane. Sham control animals were 
exposed to anesthesia, skull exposure, and suturing without the cortical impact. The amount 
of deformation was set at either 0.5 mm (moderate injury) or 1.0 mm (severe injury). After 
injury, animals were allowed to recover and were able to eat and drink for 4–24 hours prior 
to harvest.
Serum and BAL
After euthanization, blood was obtained from the right ventricle and centrifuged (15 min; 
1500g; 4°C) and serum was isolated. For bronchoalveolar lavage (BAL), lungs were lavaged 
with aliquots totaling 3 ml of Ca2+- and Mg2+-free PBS supplemented with 0.1 mM EDTA. 
Samples were centrifuged (10 min; 1500g; 4°C).
Pulmonary Function Tests and Arterial Blood Gases
After inducing anesthesia with 1–2% Isoflurane, all mice were mechanically ventilated with 
a rodent ventilator using room air, at a rate of 140 breaths per minute, a tidal volume of 0.3 
ml, and 2 cmH2O of positive end-expiratory pressure. The animals were placed on a heated 
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(37C°) pad and pulmonary function tests were then performed with the Flexi Vent system 
(Scireq, Montreal, PQ, Canada). At the competition of pulmonary function testing, a 25 
gauge angiocatheter was placed at the junction of the left ventricle and ascending aorta and 
2–3 mL of arterial blood was obtained. This was run on an iSTAT point-of-care analyzer 
(Abbott Laboratories, Princeton, NJ). Subsequently, mice were euthanized and lungs 
harvested in 10% neutral buffered formalin.
Histology and Lung Injury Scoring
After mice were euthanized, native and donor lungs were harvested, glutaraldehyde-fixed, 
and paraffin embedded. A portion of the each lobe of each lung was sectioned and stained 
with hematoxylin and eosin. Lungs were stained with hematoxylin and eosin and scored by a 
blinded pathologist using the Lung Injury Scoring System from the American Thoracic 
Society Workshop Report (19). This criteria gives a continuous score between 0 (no injury) 
and 1 (severe injury). Additionally, immunohistochemistry was performed on lung sections 
for Caspase-3, a marker of apoptosis.
Myeloperoxidase Levels in BAL
BAL fluid from animals was collected and myeloperoxidase (MPO) levels were measured 
using an ELISA kit (Cell Sciences, Canton, MA) according to manufacturer’s instructions.
PET/CT Cardiac Output and Image Analysis
Cardiac output was calculated using Dynamic high resolution 18F-NaF Positron Emission 
Tomography (PET) Computed Topography (CT). Subsequently, CT and PET images were 
co-registered for image analysis and the Stewart-Hamitlon indicator dilution method was 
used to calculate cardiac output using a left ventricular time activity curve. The full details 
are available in the supplemental material.
TAT-4BB Decoy Peptide
TAT-4BB was obtained from GenScript (Piscataway, NJ) containing the essential amino acid 
sequence of the TAT domain with 4BB (YGRKKRRQRRR-LHYRDRIPGVAIAA). This 
was administered via a subcutaneous 24 hour micro-osmotic pump from Alzert (Cupertino, 
CA). Vehicle was used as a negative control.
Serum HMGB1 Measurement
HMGB1 serum levels were determined by using an ELISA kit (IBL International, Hamburg, 
Germany) according to manufacturer’s instructions.
HMGB1 Neutralizing Antibody
Neutralization of HMGB1 was accomplished by administering anti-HMGB1 chicken IgY 
neutralizing polyclonal antibody (IBL International, Toronto, ON) dosed at 2mg/kg both 30 
minutes prior to TBI. Isotype matched control antibodies were administered to control 
animals with the same dosing regimen. Additionally, immunohistochemistry was performed 
on paraffin-embedded mouse lungs against HMGB1 (ab18256, Abcam, Cambridge, MA) as 
previously described (56). Brain tissue was also stained was also performed using 
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immunocytochemical and immunohistochemical methodologies previously described (57). 
Cortical tissue was serially sectioned at 14 μm and was used in immunohistochemical 
experiments. The primary antisera used was the rabbit anti-HMGB1 antibody (1:1,000; 
Sigma Aldrich). Sections were incubated in secondary donkey ant-Rabbit conjugated to CY3 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Nuclear co-
localization with DAPI was also performed and images were imported into Image-Pro Plus 
(Media Cybernetics, Silver Spring, MD, USA) for quantification.
HMGB1 Stimulated NF-κB Activation in Airway Epithelial Cells
A cell culture of rat alveolar type 2 (AT2) cells were stimulated with increasing 
concentrations of non-oxidizable LPS-free HMGB1 (HMGBiotech, Milan, Italy) at 0, 5, 10, 
and 15ug/mL for 24 hours. Nuclear and cytosolic protein lysates were then collected and 
analyzed for p50 and p65 NF-κB by Western blot analysis. Further details are supplied in 
the supplemental materials.
Cytokine profiling by cytometric bead array (CBA)
BAL fluid from animals was collected and cytokine protein levels of IL-17A, IL-10, TNF-α, 
IFN-γ, IL-6, IL-4, and IL-2 were measured using the Mouse Th1/Th2/Th17 Cytokine Kit 
(BD Biosciences, San Jose, CA) according to manufacturer’s instructions.
Murine Orthotopic Left Lung Transplantation
All surgical procedures were performed utilizing sterile techniques in a previously described 
method (58) which is detailed in the supplemental materials.
Statistical Analysis
Data were normally distributed and analyzed statistically with GraphPad Prism (GraphPad 
Software Inc., San Diego, CA). Results are expressed as means ± SEM. Differences between 
groups were analyzed by unpaired t-tests and analysis of variance and Tukey post hoc test. 
Correlation coefficient between two variables was calculated with the Pearson correlation 
test. P values not exceeding 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Acute lung injury in C57BL/6 mice 4–24 hours after TBI. Representative H/E histology 
sections of C57BL/6 mouse lungs after traumatic brain injury at various time points. (A) 
Control animals with sham TBI. (B) 4 hours after TBI with alveolar hemorrhage. (C) 8 
hours after TBI with alveolar hemorrhage. (D) 12 hours after TBI with interstitial 
neutrophils. (E) 24 hours after TBI with interstitial neutrophils. (F) Acute lung injury scores 
from a blinded pathologist based on a standardized scoring system from the American 
Thoracic Society (19). Scores are continuous between 0 and 1 with 0 representing no injury 
and 1 representing severe acute lung injury. (G) Albumin concentrations in BAL fluid after 
TBI. (H) Systemic concentrations of HMGB1 24 hours after severe TBI in the sham injured 
group as well as in C57BL/6 and RAGE −/− mice 24 hours after TBI. n=6–8 per condition, 
Student’s t test comparison with the reference sham injured group, comparisons versus 
sham-injured group, *p<0.01.
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Figure 2. 
PaO2/FiO2 ratios and compliance values derived from C57BL/6 and RAGE −/−mice 4–24 
hours after TBI. (A) PaO2/FiO2 ratios from controls without TBI and wildtype mice 4–24 
hours after TBI. (B) Static compliance values obtained via Pulmonary Function Testing from 
controls without TBI and wildtype mice 4–24 hours after TBI. (C) PaO2/FiO2 ratios from 
C57BL/6 and RAGE−/− 24 hours after TBI. Animals were administered either moderate or 
severe TBI. (D) Compliance values from controls and C57BL/6 and RAGE −/− mice 24 
hours after TBI. n=4–7 mice per condition, comparisons versus sham-injured group unless 
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otherwise indicated, *p<0.01 Statistical testing included unpaired t-tests and analysis of 
variance.
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Figure 3. 
PaO2/FiO2 ratios and compliance values 24 hours after TBI in RAGE −/−, TLR4 −/− mice 
treated with HMGB1 neutralizing antibody, and mice treated with TAT-4BB decoy peptide. 
(A) PaO2/FiO2 ratios in control mice and RAGE −/−, TLR4 −/− mice treated with HMGB1 
antibody or control antibody, or treated with 4BB (Myd-88) decoy peptide 24 hours after 
TBI. (B) Compliance values in RAGE −/−, TLR4 −/− mice treated with HMGB1 antibody 
or control antibody, or with 4BB decoy peptide 24 hours after TBI. n=5–7 per condition, 
comparisons versus sham-injured group unless otherwise indicated, *p≤0.01. Statistical 
testing included unpaired t-tests and analysis of variance.
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Figure 4. 
Histology and acute lung injury scores for transplanted left lungs from control donor mice, 
wildtype TBI donor mice, or RAGE−/− TBI donor mice. Representative H/E histology 
sections from transplanted lungs 5 days after transplant. (A) Transplanted left lung from 
healthy donor with sham TBI. (B) Transplanted left lung from wildtype TBI donor. (C) 
Transplanted left lung from RAGE−/− TBI donor. (D) Acute lung injury scores from 
transplant recipients who received lungs from three different donors: wildtype animals with 
sham TBI, wildtype animals with TBI, and RAGE −/− donors with TBI. n=6–8 per 
condition, comparison versus sham-injured group, *p<0.01. Statistical testing included 
unpaired t-tests and analysis of variance
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Figure 5. 
BAL cytokine profiles in control and injured donor mice 24 hours after TBI. Cytokine 
profiling was also performed in left lung transplant recipients of TBI donor lungs 8 hours 
after transplant. (A–F) Mean Fluorescence Intensity of IL-4, IL-6, IL-17a, IFN-γ, TNF-α, 
IL-17A, and IL-10. n=5–7 per condition, *p<0.01. Statistical testing included unpaired t-
tests and analysis of variance
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Figure 6. 
Representative Western blot of NF-κB activation in rat alveolar type 2 (AT2) cells following 
exposure to HMGB1. (A) NF-κB p65 and p50 translocation from the cytoplasm to the 
nucleus demonstrated by stimulating AT2 cells with 0, 5, or 10 μg/mL of HMGB1 for 24 
hours. (B–E) Densitometric analysis was performed using GAPDH as a loading control for 
the cytoplasmic samples and Lamin B1 as a loading control for the intranuclear samples.
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Figure 7. 
PaO2/FiO2 ratios in lung transplant donors and recipients based on donor HMGB1 serum 
concentrations at the time of harvest. (A) PaO2/FiO2 ratios among all brain dead donors, 
regardless of mechanism of injury correlated with donor HMGB1 serum concentrations at 
harvest. (B) PaO2/FiO2 ratios among brain dead donors whose mechanism of injury was 
TBI, and donor HMGB1 serum concentrations at harvest. (C) Recipient PaO2/FiO2 ratios at 
48 hours after transplant correlated with donor HMGB1 serum concentrations at harvest. (D) 
Recipient PaO2/FiO2 ratios at 48 hours after transplant from brain dead donors whose 
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mechanism of injury was TBI correlated with donor HMGB1 serum concentrations at 
harvest.
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Table 1
Donor, Recipient, and Surgery Characteristics (n=18)
Donor Characteristics
Male sex, n (%) 7 (39)
Age, mean 34.2
Mode of death, n (%)
 Traumatic Brain Injury 11 (61)
 Anoxia 4 (22)
 Stroke 3 (17)
Race, n (%)
 White 12 (67)
 African American 5 (28)
 Other 1 (6)
Recipient Characteristics
Male sex, n (%) 11 (61)
Age, mean 55.3
Pulmonary Diagnosis
 COPD 11 (61)
 Idiopathic Pulmonary Fibrosis 5 (28)
 Pulmonary Arterial Hypertension 1 (6)
 Cystic Fibrosis 1 (6)
Surgery Characteristics
Transplant type, double, n (%) 18 (100)
Ischemia time in mins, mean 314
18 bilateral lung transplants were performed and donor, recipient, and operative variables were recorded. All donor lungs were donated after brain 
death.
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